R. Lam

Effect of malignancy rates on cost-effectiveness of routine gene expression classifier testing for indeterminate thyroid nodules.

J. Rao, James X. Wu, M. Yeh, 2016, Surgery.

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

A. Oza, G. Shapiro, J. Schellens, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume

D. Bergstrom, C. Parkinson, J. Brenton, 2014, Clinical Cancer Research.

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).

M. Minden, H. Kantarjian, F. Ravandi, 2015, Leukemia research.

Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

A. Oza, G. Shapiro, J. Schellens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.

D. Hong, U. Banerji, N. Somaiah, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Making Sense of Human Lung Carcinomas Gene Expression Data: Integration and Analysis of Two Affymetrix Platform Experiments

Xiwu Lin, Sergio Eslava, Xiwu Lin, 2005 .

Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitor.

A. Oza, G. Shapiro, J. Schellens, 2012 .

Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy

A. Pavlick, L. Dauffenbach, G. Herman, 2014 .